Analysts Highlight Oversold Biotech Stock Amid Market Rally
While equity markets surge in 2025, contrarian investors are scouring the wreckage of oversold stocks for turnaround candidates. Xencor, a monoclonal antibody specialist, has drawn particular attention after its 35%+ decline this year. The biopharma's XmAb protein engineering platform shows promise for treating autoimmune disorders and cancers through targeted structural modifications.
Wall Street remains bullish despite the selloff, with analysts maintaining Strong Buy ratings and projecting significant upside. The divergence between market performance and fundamental potential creates what some see as an asymmetric opportunity—though biotech volatility demands careful risk assessment.